NeuroSense Therapeutics (NRSN) details special shareholder meeting outcomes

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to report that it held a Special Meeting of Shareholders on December 30, 2025. The filing states that shareholders approved certain resolutions at the meeting, but does not detail the specific matters that were voted on. The report, excluding the fourth paragraph in Exhibit 99.1, is incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3, meaning this information becomes part of those securities registration documents.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of January 2026

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building B

Herzliya 4672562 Israel

+972-9-9531142

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Annual Meeting of Shareholders

On December 30, 2025, NeuroSense Therapeutics Ltd. (the “Company”) held a Special Meeting of Shareholders (the “Meeting”). At the Meeting, the following resolutions were approved by shareholders:

1. The grant of restricted shares to the non-management directors of the Company for 2024.

2. The grant of restricted shares to the non-management directors of the Company as equity compensation in lieu of deferred cash fees to maintain financial flexibility.

3. The grant of restricted shares to Alon Ben-Noon, the Company’s Chief Executive Officer and a director of the Company.

This Report on Form 6-K (other than the fourth paragraph in Exhibit 99.1) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-269306, 333-260338, 333-283656, 333-284051 and 333-291122) to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: January 6, 2026	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2

FAQ

What did NeuroSense Therapeutics (NRSN) report in its January 2026 Form 6-K?

NeuroSense Therapeutics reported that it held a Special Meeting of Shareholders on December 30, 2025, where shareholders approved certain resolutions.

When was NeuroSense Therapeutics’ Special Meeting of Shareholders held?

The Special Meeting of Shareholders was held on December 30, 2025.

Were resolutions approved at NeuroSense Therapeutics’ December 30, 2025 shareholder meeting?

Yes, the company states that shareholders approved resolutions at the Special Meeting, though specific details are not provided in this excerpt.

How is this NeuroSense Therapeutics Form 6-K used in existing registration statements?

The Form 6-K, other than the fourth paragraph in Exhibit 99.1, is incorporated by reference into NeuroSense’s Form S-8 and Form F-3 registration statements.

Which registration statements does this NeuroSense Therapeutics Form 6-K affect?

It is incorporated by reference into Form S-8 Registration Statements File Nos. 333-262480 and 333-289658, and Form F-3 Registration Statements File Nos. 333-269306, 333-260338, 333-283656, 333-284051 and 333-291122.

Who signed NeuroSense Therapeutics’ January 2026 Form 6-K?

The Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon, Chief Executive Officer.